Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Shionogi President Urges Govt to Stockpile Infectious Disease Drugs
October 14, 2021
- MSD, Maruho Warn of Ivermectin Prescribing for COVID-19, Stressing Such Use Not Approved
October 14, 2021
- Abraxane Supply to Continue until Mid-December without Possible Stockouts: Taiho
October 13, 2021
- Japan Drug Makers Prepping to Launch New Organization to Solve Challenges in Digital Health
October 13, 2021
- Lack of Management Response, Tight Manufacturing Plans to Blame in Choseido Issue: Report
October 12, 2021
- Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
- Sales Reps’ Detailing Activities Decrease by 3.4% in August: Intage
October 12, 2021
- Ivermectin COVID-19 Trial Needed Because Evidence Is Lacking, Kowa Says as It Aims for PIII Wrap-Up in November
October 11, 2021
- Takeda’s CMV Drug Maribavir Earns FDA AdCom Backing
October 11, 2021
- Licensing Izcargo to Takeda First Step to Expanded Application of JCR’s BBB-Penetrating Technology: Chairman
October 8, 2021
- Kyowa Kirin Calls Off Entinostat Breast Cancer Program in Japan
October 8, 2021
- Japan Ethical Drug Sales Zoom 8.8% in August: Crecon
October 8, 2021
- Otsuka Gets EU Nod for Pediatric Formulation of TB Drug Deltyba
October 7, 2021
- Opdivo Top-Selling Drug in Japan in September: Encise
October 7, 2021
- Takeda Suspends PII Trials of Narcolepsy Drug Hopeful on Safety Concerns
October 7, 2021
- Asahi Kasei Aims for Pharma Sales of 150 Billion Yen by FY2025
October 6, 2021
- Oncolys Aims to Bring Nucleocapsid Inhibitor into Clinic Next Year for COVID-19 Treatment
October 6, 2021
- JCR’s Hurler Syndrome Drug Earns Fast-Track Status in US
October 6, 2021
- Streamline Regulatory Approval Process with Overseas Data: Rakuten Chief
October 5, 2021
- Astellas to Accelerate Drug Discovery by Forming Specialized Small Teams by Modality: CScO
October 5, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…